DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Regdanvimab
Regdanvimab
Progress in the Development of Potential Therapeutics and Vaccines Against COVID-19 Pandemic
Policy Brief 002 Update 07.2021
Regdanvimab for the Treatment of COVID-19
May 2021 Monitoring International Trends
Policy Brief 002 Update 04.2021.Pdf
Korean Society of Infectious Diseases/National Evidence-Based
Medizinische Biotechnologie in Deutschland 2021
Interim Clinical Guidance for Adults with Suspected Or Confirmed Covid-19 in Belgium
COVID-19: Unmasking Emerging SARS-Cov-2 Variants, Vaccines and Therapeutic Strategies
Regdanvimab for the Treatment of COVID-19 (Celltrion) Art. 5(3
Neutralizing Antibody Therapeutics for COVID-19
Policy Brief 002 Update 06.2021
Newsletter: Human Medicines Highlights
Monoclonal Antibodies
A Single Intramuscular Injection of Monoclonal Antibody MAD0004J08
Human Medicines Highlights Newsletter
COVID-19: Unmasking Emerging SARS-Cov-2 Variants, Vac- Cines and Therapeutic Strategies
The in Vitro and in Vivo Potency of CT-P59 Against Delta and Its Associated
Top View
Revealing the Threat of Emerging SARS-Cov-2 Mutations to Antibody Therapies
PDF of Antibody News
Therapeutic Effect of CT-P59 Against SARS-Cov-2 South African Variant
SARS-Cov-2 Report 6 April 2021 Contents
SARS-Cov-2 Immune Evasion by Variant B.1.427/B.1.429 2 3 4 Matthew Mccallum1*, Jessica Bassi2*, Anna De Marco2*, Alex Chen3*, Alexandra C
ATAD00705-Regdanvimab(CT-P59 )
Mouse Antibodies with Activity Against the SARS-Cov-2 D614G and B.1.351 Variants
Access to Vaccines, Therapeutics, and Diagnostics
SARS-Cov-2 501Y.V2 Escapes Neutralization by South African COVID-19 Donor Plasma
COVID-19 Therapeutics Strategy
Eunethta Joint Action 3 WP4
COVID-19: Failure of the Discovery Clinical Trial, and Now–New Hopes?
Ra Capital's Covid-19 Map
Antibody News You Should Know January 1 - 15, 2021